Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28081480 | 0.85 | F2 (0.38) | NOS2CA2 | |
| SCHEMBL28170293 | 0.85 | GNAI3 (0.34) | GNAI3GNAO1GNAI1NOS2 | |
| Hydrochloric Acid SCHEMBL28169769 | 0.83 | GNAI3 (0.37) | GNAI3GNAO1GNAI1NOS2 | |
| SCHEMBL3067680 | 0.82 | CA12 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL3913611 | 0.80 | GNAI3 (0.39) | GNAI3GNAO1GNAI1CA12CA1 | |
| SCHEMBL4985794 | 0.77 | — | — | |
| SCHEMBL1459326 | 0.76 | GNAI3 (0.44) | GNAI3GNAO1GNAI1CA12CA1 | |
| SCHEMBL1132836 | 0.76 | GNAI3 (0.37) | GNAI3GNAO1GNAI1CA12CA1 | |
| Iodide SCHEMBL28724371 | 0.75 | F2 (0.40) | — | |
| SCHEMBL4986694 | 0.75 | F2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165106-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20220054479-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11197933-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-11129825-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200101166-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2020-04-02 | — | — | US | disclosed |
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190183884-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10251878-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| EP-3355885-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | Elysium Therapeutics, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170368058-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9808452-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170100390-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2017-04-13 | — | — | US | disclosed |
| EP-2026754-A2 | LIGHTENING AND/OR COLOURING AGENT COMPRISING CYCLIC UREA DERIVATIVES | Henkel AG & Co. KGaA (DE) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007137676-A2 | LIGHTENING AND/OR COLOURING AGENT COMPRISING CYCLIC UREA DERIVATIVES | HENKEL AG & CO. KGAA (DE) | 2007-12-06 | — | — | WO | disclosed |
| WO-1999011612-A2 | SUBSTITUTED CYCLIC COMPOUNDS AND MIXTURES COMPRISING SAME | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | GNAI3 1417/4885GNAO1 712/4885GNAI1 1222/4885 |
| US-10251878-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | OPRK1, OPRM1, CYP3A5 | GNAI3 1868/4885GNAO1 1474/4885GNAI1 1519/4885 |
| US-11197933-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | OPRM1, OPRK1, OPRL1 | GNAI3 165/4885GNAO1 91/4885GNAI1 81/4885 |
| US-20240165106-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | GNAI3 1868/4885GNAO1 1474/4885GNAI1 1519/4885 |
| US-20220054479-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | GNAI3 1417/4885GNAO1 712/4885GNAI1 1222/4885 |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | GNAI3 1417/4885GNAO1 712/4885GNAI1 1222/4885 |
| US-20200101166-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRL1 | GNAI3 165/4885GNAO1 91/4885GNAI1 81/4885 |
| US-20170100390-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | GNAI3 1868/4885GNAO1 1474/4885GNAI1 1519/4885 |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | GNAI3 1417/4885GNAO1 712/4885GNAI1 1222/4885 |
| US-20170368058-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | GNAI3 1868/4885GNAO1 1474/4885GNAI1 1519/4885 |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | GNAI3 1868/4885GNAO1 1474/4885GNAI1 1519/4885 |
| US-11129825-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | OPRK1, OPRM1, CYP3A5 | GNAI3 1868/4885GNAO1 1474/4885GNAI1 1519/4885 |
| US-20190183884-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | GNAI3 1868/4885GNAO1 1474/4885GNAI1 1519/4885 |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | GNAI3 1417/4885GNAO1 712/4885GNAI1 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.